崇達技術(002815.SZ):目前服務器客戶有中興、新華三(H3C)、雲尖、寶德、浪潮、國鑫、同泰怡等
格隆匯3月17日丨崇達技術(002815.SZ)在投資者互動平臺表示,公司目前服務器客戶有中興、新華三(H3C)、雲尖、寶德、浪潮、國鑫、同泰怡等,PCB產品主要應用於超級計算機、服務器主板、存儲設備、GPU(圖形處理器,Graphics Processing Unit)等。通用服務器方面,Eagle Stream平臺已經批量出貨了,正在配合客戶開展新一代BHS(Birth Stream)平臺的小批量試製,以及下一代OAK Stream平臺的預研;AI服務器方面,目前我們通過雲尖-之江GPU算力項目與百度、曦智、天數等國產GPU實現小批量出貨。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.